글로벌 골반 울혈 증후군 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

골반 울혈 증후군 시장 분석

최소 침습적 시술은 전통적인 수술에 비해 회복 시간이 단축되고 합병증 발생률이 낮아 효과적인 치료 옵션을 제공함으로써 골반 울혈 증후군(PCS) 관리에 중요한 역할을 합니다. 사용되는 주요 시술 중 하나는 골반 정맥 색전술로, 영상 안내 하에 영향을 받는 정맥에 카테터를 삽입합니다. 이 시술을 통해 색전제를 투여하여 정맥류를 차단하고 골반 통증 및 불편함과 같은 증상을 완화합니다. 이 접근 방식은 PCS의 근본 원인을 해결하고 더 빠른 회복과 최소한의 흉터를 촉진하여 PCS 증상에서 장기적인 완화를 추구하는 많은 환자에게 선호되는 선택입니다.

골반 울혈 증후군 시장 규모

글로벌 골반 울혈 증후군 시장 규모는 2023년에 6억 8,013만 달러로 평가되었으며, 2031년까지 1,130.69만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.56%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

골반 울혈 증후군 시장 정의

Pelvic congestion syndrome (PCS) is a chronic condition characterized by persistent pelvic pain, typically caused by varicose veins in the pelvic region. These veins become enlarged and dilated, leading to discomfort, heaviness, and aching sensations. PCS predominantly affects women of childbearing age and is associated with symptoms exacerbated by prolonged standing, menstruation, or sexual activity.

Pelvic Congestion Syndrome Market Dynamics

Drivers                                                                                          

• Increasing Healthcare Expenditure

As healthcare budgets expand, there is greater investment in research, diagnostic technologies, and treatment options for conditions such as PCS. This financial support enables healthcare providers to improve patient outcomes through early diagnosis and advanced treatments such as minimally invasive procedures such as pelvic vein embolization. Moreover, higher healthcare spending facilitates the development of specialized healthcare facilities and the training of healthcare professionals in managing PCS. Ultimately, increased expenditure enhances access to comprehensive care, raises awareness among both healthcare providers and patients, and drives innovation in PCS management strategies, thereby bolstering the overall growth of the PCS market.

• Increasing Awareness of Pelvic Congestion Syndrome

As awareness increases, more patients are accurately diagnosed with PCS, leading to greater demand for treatments and management options. This recognition is fueled by improved understanding of PCS symptoms, which include chronic pelvic pain, discomfort, and associated complications such as dyspareunia (painful intercourse) and lower quality of life. Healthcare providers are increasingly incorporating PCS into differential diagnoses, prompting earlier referrals for specialized care and treatment interventions such as minimally invasive procedures such as pelvic vein embolization. Ultimately, enhanced recognition of PCS supports the expansion of healthcare services and treatment modalities tailored to meet the needs of affected patients, driving market growth in this specialized area of gynecological and interventional radiology practices.

Opportunities

• Growing Healthcare Infrastructure Development

Healthcare infrastructure development enhances access to specialized treatment and diagnostic facilities. This includes the establishment and expansion of gynecological clinics, interventional radiology departments, and pain management centers equipped to diagnose and treat PCS effectively. Improved infrastructure allows for the adoption of advanced imaging technologies such as ultrasound and pelvic venography, facilitating accurate diagnosis and monitoring of PCS. Additionally, infrastructure development supports the delivery of minimally invasive procedures such as pelvic vein embolization, which require specialized equipment and trained healthcare professionals.

• Growing Technological Advancements in Treatment

Technological advancements in the treatment of pelvic congestion syndrome (PCS) have significantly influenced the market by offering more effective and less invasive options for managing symptoms. One key advancement is pelvic vein embolization, a minimally invasive procedure where varicose veins in the pelvic region are targeted and blocked off using embolic agents delivered through a catheter. This approach reduces the need for traditional open surgeries, leading to shorter recovery times, lower risks of complications, and improved patient outcomes. Moreover, advancements in imaging techniques such as pelvic congestion syndrome ultrasound, and computed tomography (CT) scans enhance the precision of diagnosis and treatment planning for PCS, further driving the adoption of these advanced therapies. As technology continues to evolve, it is expected to further expand treatment options and improve quality of life for PCS patients globally.

Restraints/Challenges

• Limited Treatment Options

While minimally invasive procedures such as pelvic vein embolization are effective for many patients, access to these specialized treatments can be limited in certain geographic areas or healthcare settings. This limitation may result in delayed diagnosis and management, impacting patient outcomes and quality of life. Additionally, conservative treatment options such as pain management and lifestyle modifications may not always provide adequate relief for all PCS patients, highlighting the need for broader access to a variety of therapeutic approaches.

• High Treatment Costs

Diagnostic procedures such as ultrasound and pelvic venography, which are essential for accurate PCS diagnosis, can be expensive. Moreover, minimally invasive treatments such as pelvic vein embolization involve specialized equipment and skilled healthcare professionals, contributing to higher overall treatment expenses. Insurance coverage and reimbursement policies may not fully support these costs, leading to financial burdens for patients and healthcare providers. The affordability gap often hinders timely access to optimal care, particularly in regions with limited healthcare resources or for patients without adequate insurance coverage.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pelvic Congestion Syndrome Market Scope

The market is segmented on the basis of type and application. The growth amongst these segments will help your meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Type

• NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
• Dihydroergotamine

Application

• Primary Pelvic Congestion Syndrome
• Secondary Pelvic Congestion Syndrome

Pelvic Congestion Syndrome Market Regional Analysis

The market is analyzed and market size information is provided by country by type and application as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Peru, Brazil, Argentina and Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA).

North America dominates the market due to the region benefits from rapid advancements in medical technology, which facilitate accurate diagnosis and effective treatment options for PCS. Healthcare facilities in North America are well-equipped with state-of-the-art infrastructure and resources, enabling comprehensive care delivery to patients with PCS. Additionally, there is a strong emphasis on research and development within the healthcare sector, leading to continuous innovation in PCS management strategies.

아시아 태평양 지역은 골반 울혈 증후군(PCS)의 유병률 증가로 인해 시장에서 상당한 성장을 경험할 것으로 예상됩니다. 골반 정맥류로 인해 종종 발생하는 만성 골반 통증을 특징으로 하는 이 질환은 이 지역 전체에서 점점 더 인식되고 진단되고 있습니다. 의료 서비스 제공자와 환자의 인식 증가와 진단 기술의 발전이 이러한 성장을 촉진하고 있습니다. 또한 의료 인프라를 개선하고 전문 치료 옵션에 대한 접근성을 확대하는 것이 예측 기간 동안 아시아 태평양 지역에서 예상되는 PCS 사례 증가와 그에 따른 의료비 지출에 더욱 기여하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

골반 울혈 증후군 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 노바티스 AG(스위스)
• 사노피(프랑스)
• 톨마제약(미국)
• Actiza Pharmaceutical Private Limited(인도)
• 파이저 주식회사(미국)
• AbbVie Inc.(미국)
• GlaxoSmithKline plc (영국)
• 베링거인겔하임인터내셔널(독일)
• Bayer AG(독일)
• 아스트라제네카(영국)
• 인디비어 PLC(영국)
• 다케다제약 주식회사(일본)
• 프레제니우스 카비 USA(US)

골반 울혈 증후군 시장의 최신 동향

• 2020년 11월, 로슈 그룹의 일원인 제넨텍은 미국 FDA가 Xofluza(baloxavir marboxil)에 대한 보충 신약 승인(sNDA)을 승인했다고 발표했습니다. 이 승인으로 Xofluza는 독감에 걸린 사람과 접촉한 12세 이상의 개인에게 독감을 예방하기 위한 단일 복용 치료제로 사용할 수 있게 되었으며, 이는 노출 후 예방을 위해 승인된 최초의 의약품이 되었습니다.

SKU-62950